Interleukin 1 inhibition with anakinra in adult-onset Still disease: a meta-analysis of its efficacy and safety
1. 系统已在2025-08-20 09:15:10对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
D Hong, Z Yang, S Han, X Liang, K Ma…
Drug Design …, 2014
Taylor & Francis
Background Anakinra is the first interleukin-1 inhibitor to be used in clinical practice, and recent evidence showed that interleukin-1 plays a pivotal role in the pathogenesis of adult-onset Still disease (AoSD). However, data concerning efficacy with anakinra use in different clinical trials has not been evaluated, and the overall remission of AoSD with anakinra treatment has not been well defined. Methods We conducted a search on Embase, PubMed, and the Cochrane Library for relevant trials. Statistical analyses were conducted to calculate …
